(39 days)
Not Found
Not Found
No
The document describes a light-based medical device and does not mention AI, ML, or any related concepts in the device description, intended use, or other sections.
Yes
The device is intended for the treatment of various medical conditions such as inflammatory acne vulgaris, benign pigmented epidermal lesions, cutaneous lesions, and benign cutaneous vascular lesions, which indicates its therapeutic purpose.
No.
The device description indicates that the Chromolite™ EP System is an Intense Pulsed Light-based medical device used for light-based therapies such as the treatment of acne, pigmented lesions, vascular lesions, and hair removal. It is not described as detecting or diagnosing medical conditions.
No
The device description explicitly states it is an "Intense Pulsed Light-based medical device utilising xenon flashlamp technology," which are hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Device Description and Intended Use: The Chromolite™ EP System is described as an Intense Pulsed Light-based medical device used for aesthetic and cosmetic applications directly on the patient's skin. Its indications for use involve treating various skin conditions and removing hair.
- Lack of Specimen Analysis: There is no mention of the device analyzing any biological specimens taken from the patient.
Therefore, the Chromolite™ EP System is a therapeutic device that applies light energy directly to the body, not an IVD.
N/A
Intended Use / Indications for Use
Indications for use for Fitzpatrick skin types (I to V).
The Chromolite™ EP System is intended for use in aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostatis of soft tissue in the medical specialities of plastic surgery and dermatology as follows:-
Indications for use for Fitzpatrick skin types (I to V).
- . The treatment of moderate inflammatory acne vulgaris
- The treatment of benign pigmented epidermal lesions including dyschromia, hyper-. pigmentation, melasma, ephelides (freckles)
- . The treatment of cutaneous lesions including warts,scars, and striae.
- . The treatment of benign cutaneous vascular lesioins, including port wine stains, hemamangiomas, facial, truncal, and leg telangiectasias, erythema of rosacea, angiomas, and spider angiomas, poikiloderma of civatte, leg veins and venous malformations.
- . The removal of unwanted hair and to effect stable long-term or permanent hair reduction.
1 = Permanent hair reduction is defined as a long-term stable reduction in the number of hairs re-growing after a treatment regimen.
Product codes
GEX
Device Description
The Chromolite™ EP System is an Intense Pulsed Light-based medical device utilising xenon flashlamp technology to illuminate, to offer light based therapies as listed in the indications for use. The Chromolite" " EP System emits light at 390nm to 1200nm via a 50mm x 15mm waveguide at a repetition rate of up to 0.5Hz.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Chomolite™ System
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
0
510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: K081619
Submitter: A.
Chromogenex Technologies Limited Units 1-2 Heol Rhosyn Parc Dafen Llanelli Carmarthenshire Great Britain
Phone: +44 (0) 1554 755444 +44 (0) 1554 755333 Fax:
Contact: Mr Peter R Bevan (Quality Manager)
Date Prepared: 30th April 2008
B. Device Names:
| Classification name | Laser Surgical Instrument 21 C.F.R 878.4810 |
|---|---|
| Common/usual name | Chromolite - Intense Pulsed Light (IPL) |
| Proprietary name | ChromoliteTM EP |
Chromolite™ System C. Predicate Device:
Device Description: D.
The Chromolite™ EP System is an Intense Pulsed Light-based medical device utilising xenon flashlamp technology to illuminate, to offer light based therapies as listed in the indications for use. The Chromolite" " EP System emits light at 390nm to 1200nm via a 50mm x 15mm waveguide at a repetition rate of up to 0.5Hz.
Intended Use: E.
Indications for use for Fitzpatrick skin types (I to V).
The Chromolite™ EP System is intended for use in aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostatis of soft tissue in the medical specialities of plastic surgery and dermatology as follows:-
1
Special 510(k): Device Modification Chromolite™ EP
Indications for use for Fitzpatrick skin types (I to V).
- The treatment of moderate inflammatory acne vulgaris .
- The treatment of benign pigmented epidermal lesions including dyschromia, hyper-. pigmentation, melasma, ephelides (freckles)
- The treatment of cutancous lesions including warts,scars, and striae. .
- The treatment of benign cutaneous vascular lesioins, including port wine stains, . hemamangiomas, facial, truncal, and leg telangicctasias,erythema of rosacea,angiomas, and spider angiomas, poikiloderma of civatte, leg veins and venous malformations.
- The removal of unwanted hair and to effect stable long-term or permanent hair reduction. .
1 = Permanent hair reduction is defined as a long-term stable reduction in the number of hairs re-growing after a treatment regimen.
Comparison with the Predicate Device: F.
The Chromolite™ EP System is a hardware and software modification of the previously cleared Chomolite™ System. The Chromolite™ EP and the Chomolite™ System have the same intended use and use the same operating principle.
Based on the data and information presented here, the Chromolite™ EP System is substantially equivalent to the Chomolite™ System currently manufactured and distributed by Chromogenex Technologies Limited.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus, which is a symbol often associated with medicine and healthcare. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the caduceus.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Chromogenex Technologies Limited % Mr. Peter R. Bevan Quality Manager Units 1-2 Heol Rhosyn Parc Dafen Ind. Est. Llanelli Carmarthenshire SA14 8QG Great Britain
JUL 1 8 2008
Re: K081619
Trade/Device Name: Chromolite™ EP System Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: II Product Code: GEX Dated: May 23, 2008 Received: July 7, 2008
Dear Mr. Bevan:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must
3
Page 2 - Mr. Peter R. Bevan
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
Mark N. Mulhern
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Special 510(k): Device Modification Chromolite™ EP
Indications for Use
510(k) Number (if known): K081619
Device Name: _ Chromolite™ EP System _________________________________________________________________________________________________________________________________________
Indications for use for Fitzpatrick skin types (I to V).
The Chromolite™ EP System is intended for use in aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostatis of soft tissue in the medical specialities of plastic surgery and dermatology as follows:-
Indications for use for Fitzpatrick skin types (I to V).
- . The treatment of moderate inflammatory acne vulgaris
- The treatment of benign pigmented epidermal lesions including dyschromia, hyper-. pigmentation, melasma, ephelides (freckles)
- . The treatment of cutaneous lesions including warts,scars, and striae.
- . The treatment of benign cutaneous vascular lesioins, including port wine stains, hemamangiomas, facial, truncal, and leg telangiectasias, erythema of rosacea, angiomas, and spider angiomas, poikiloderma of civatte, leg veins and venous malformations.
- . The removal of unwanted hair and to effect stable long-term or permanent hair reduction.
1 = Permanent hair reduction is defined as a long-term stable reduction in the number of hairs re-growing after a treatment regimen.
Prescription Use _____________________________________________________________________________________________________________________________________________________________ Subpart D)
Over-The-Counter Use ______ (21 CFR 801 AND/OR (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Division of General, Restorative, and Neurological Devi
510(k) Number L041614